Jubilant Pharmova
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Jubilant Pharmova is navigating a pivotal transition towards high-margin, complex manufacturing and specialized radiopharmaceuticals, as highlighted by management's 'Vision 2030' roadmap aimed at doubling revenues across key segments. The company's aggressive expansion of its US-based sterile injectable capacity is timely, given the increasing demand for domestic manufacturing spurred by the Biosecure Act. However, short-term challenges, including FDA-related remediation at its Montreal facility and competitive pricing pressures in legacy segments, may temper growth. Vista's forecast anticipates low double-digit revenue growth for FY2027, supported by strategic initiatives in high-value biologics and custom manufacturing, which are expected to enhance margins in the latter half of the fiscal year. The macro environment remains favorable, with a stable inflation outlook and strong manufacturing activity in India, further bolstering the company's growth prospects. Over the next 12-24 months, key opportunities include the commercialization of new products and the expansion of the Ruby-Fill franchise, while watchpoints include regulatory approval timelines and execution risks associated with site stabilization
Why We Like This Stock
- Management's strategic pivot towards high-margin, complex manufacturing is expected to drive revenue growth
- Expansion of US-based sterile injectables aligns with increasing domestic manufacturing demand
- Long-term margin expansion anticipated from the transition to high-value biologics and custom manufacturing
Things To Watch Out For
- Short-term headwinds from FDA remediation at the Montreal facility may impact operational performance
- Competitive pricing pressures in legacy segments could constrain margins
- Execution risks related to regulatory approvals and site stabilization may affect growth timelines
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 6,703 | 7,234 | 8,280 | 8,708 | 9,410 |
| Profit Before Tax (Cr.) | 339 | 621 | 673 | 559 | 644 |
| PBT Margin | 5.1% | 8.6% | 812.8% | 6.4% | 6.8% |
| Net Profit (Cr.) | -64 | 486 | 492 | 414 | 476 |
| Earnings Per Share | -3.8 | 31.0 | 31.2 | 26.1 | 30.1 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. The company serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.